<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Wu X</submitter><funding>HHS | National Institutes of Health</funding><funding>Bayerisches Staatsministerium für Bildung und Kultus, Wissenschaft und Kunst</funding><funding>The institute for Basic science, Korea</funding><funding>NIDCR NIH HHS</funding><funding>KRIBB, Korea</funding><funding>NIAID NIH HHS</funding><funding>NCI NIH HHS</funding><pagination>e0040222</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9040823</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>13(2)</volume><pubmed_abstract>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection triggers cytokine-mediated inflammation, leading to a myriad of clinical presentations in COVID-19. The SARS-CoV-2 open reading frame 8 (ORF8) is a secreted and rapidly evolving glycoprotein. Patients infected with SARS-CoV-2 variants with ORF8 deleted are associated with mild disease outcomes, but the molecular mechanism behind this is unknown. Here, we report that SARS-CoV-2 ORF8 is a viral cytokine that is similar to but distinct from interleukin 17A (IL-17A) as it induces stronger and broader human IL-17 receptor (hIL-17R) signaling than IL-17A. ORF8 primarily targeted blood monocytes and induced the heterodimerization of hIL-17RA and hIL-17RC, triggering a robust inflammatory response. Transcriptome analysis reveal</pubmed_abstract><journal>mBio</journal><pubmed_title>Viral Mimicry of Interleukin-17A by SARS-CoV-2 ORF8.</pubmed_title><pmcid>PMC9040823</pmcid><funding_grant_id>BMBF SenseCoV2 01KI20172A</funding_grant_id><funding_grant_id>DE027888</funding_grant_id><funding_grant_id>R35 CA200422</funding_grant_id><funding_grant_id>R01 DE028521</funding_grant_id><funding_grant_id>R01 AI140705</funding_grant_id><funding_grant_id>R01 AI140718</funding_grant_id><funding_grant_id>R01 CA251275</funding_grant_id><funding_grant_id>AI152190</funding_grant_id><funding_grant_id>CA200422</funding_grant_id><funding_grant_id>K99 DE028573</funding_grant_id><funding_grant_id>DE023926</funding_grant_id><funding_grant_id>AI140705</funding_grant_id><funding_grant_id>KGM9942011</funding_grant_id><funding_grant_id>IBS-R801-D1</funding_grant_id><funding_grant_id>R00 DE028573</funding_grant_id><funding_grant_id>CA251275</funding_grant_id><funding_grant_id>R01 AI152190</funding_grant_id><funding_grant_id>AI140705S1</funding_grant_id><funding_grant_id>R21 DE027888</funding_grant_id><funding_grant_id>AI140718</funding_grant_id><funding_grant_id>DE028521</funding_grant_id><funding_grant_id>R01 DE023926</funding_grant_id><funding_grant_id>DFG Fokus COVID-19 EN423/7-1</funding_grant_id><funding_grant_id>K99DE028573</funding_grant_id><pubmed_authors>Poo H</pubmed_authors><pubmed_authors>Herrmann A</pubmed_authors><pubmed_authors>Xia T</pubmed_authors><pubmed_authors>Shin WJ</pubmed_authors><pubmed_authors>Jehi L</pubmed_authors><pubmed_authors>Zhang P</pubmed_authors><pubmed_authors>Lee JS</pubmed_authors><pubmed_authors>Jung W</pubmed_authors><pubmed_authors>Choi YK</pubmed_authors><pubmed_authors>Jung JU</pubmed_authors><pubmed_authors>Ensser A</pubmed_authors><pubmed_authors>Foo SS</pubmed_authors><pubmed_authors>Chen W</pubmed_authors><pubmed_authors>Comhair SAA</pubmed_authors><pubmed_authors>Yu KM</pubmed_authors><pubmed_authors>Wu X</pubmed_authors></additional><is_claimable>false</is_claimable><name>Viral Mimicry of Interleukin-17A by SARS-CoV-2 ORF8.</name><description>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection triggers cytokine-mediated inflammation, leading to a myriad of clinical presentations in COVID-19. The SARS-CoV-2 open reading frame 8 (ORF8) is a secreted and rapidly evolving glycoprotein. Patients infected with SARS-CoV-2 variants with ORF8 deleted are associated with mild disease outcomes, but the molecular mechanism behind this is unknown. Here, we report that SARS-CoV-2 ORF8 is a viral cytokine that is similar to but distinct from interleukin 17A (IL-17A) as it induces stronger and broader human IL-17 receptor (hIL-17R) signaling than IL-17A. ORF8 primarily targeted blood monocytes and induced the heterodimerization of hIL-17RA and hIL-17RC, triggering a robust inflammatory response. Transcriptome analysis reveal</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Apr</publication><modification>2026-06-07T03:18:42.813Z</modification><creation>2025-04-20T03:08:12.831Z</creation></dates><accession>S-EPMC9040823</accession><cross_references><pubmed>35343786</pubmed><doi>10.1128/mbio.00402-22</doi></cross_references></HashMap>